HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.1%

Neg 0% Neu 88.1% Pos 0%

HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $25 price target.